International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12604 - 12604
Published: Nov. 24, 2024
Colorectal cancer (CRC) remains a significant global health challenge, ranking third in incidence and second mortality among all cancers [...].
Language: Английский
Journal of Cellular and Molecular Medicine, Journal Year: 2025, Volume and Issue: 29(4)
Published: Feb. 1, 2025
ABSTRACT Colorectal carcinoma (CRC) poses a serious risk to global human health. Long non‐coding RNAs (LncRNAs) play an important role in the pathogenesis of CRC. There is scarcity data about newly identified lncRNA, FAM30A. Our major objective investigate FAM30A process Gene expression and correlated clinical information were retrieved downloaded from public databases identify differentially expressed genes linked The was samples CRC cell lines using via Quantitative Real‐time Polymerase Chain Reaction (qPCR) assay also. survival significance determined R package “survival.” Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analysis performed FAM30A‐related signalling pathway. levels proteins by western blot assay. effect on biological behaviours evaluated function experiments. down‐regulated based database. had lower lines. Low positively related poor prognosis patients. After overexpressed, proliferation, invasion, migration abilities cells decreased, rate apoptosis increased. Furthermore, overexpression could block JAK–STAT signalling. suppresses proliferative, invasive, migratory through blocking Thus, it can be novel biomarker prognosis.
Language: Английский
Citations
1
Melanoma Research, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 28, 2025
Temozolomide is used in melanoma therapy, but the comparative efficacy and safety of monotherapy vs combination therapies are unclear. This meta-analysis evaluates temozolomide patients. PubMed, Embase, Cochrane Library were searched up to August 2024 for studies comparing with melanoma. Primary outcomes 1-year survival objective response rates (RR); secondary included hematologic non-hematologic toxicities. Data pooled using risk ratios 95% confidence intervals (CIs). Seven included. Combination improved RR over (risk ratio 0.68, CI: 0.53–0.88). One-year did not differ significantly between groups 0.81, 0.59–1.12). was associated reduced incidence leukopenia 0.54, 0.30–0.95). Adding interferon-alpha (IFN-α) 0.35–0.84) 0.57, 0.42–0.78) compared alone, without increasing toxicity. enhance monotherapy, similar survival. offers a better profile. Combining IFN-α improves Clinicians should balance when choosing treatments.
Language: Английский
Citations
0
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, Journal Year: 2025, Volume and Issue: 334, P. 125960 - 125960
Published: Feb. 26, 2025
Language: Английский
Citations
0
Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 699 - 699
Published: March 12, 2025
Background/Objectives: Research on colorectal adenoma is significantly less comprehensive compared to studies carcinoma. Although a precursor of the majority sporadic cancers, not all adenomas develop into carcinomas. The complex interaction immune responses in premalignant tumor microenvironment might be factor for that. Methods: In this systematic review, we aim provide thorough analysis current research examining infiltration patterns tissues context cell-based, cytokine-based, and other immunological factor-related changes along conventional adenoma–carcinoma sequence. articles included review extend up December 2024 PubMed Web Science databases. Results: Most have shown significant differences cell counts, densities, cytokine expression levels associated with lesions (and/or cancer). No consensus immune-related tendencies concerning CD4+T cells CD8+T was reached. Decreasing mDCs plasma naïve B were detected ACS. increased density tissue eosinophils dramatically diminishes after transition As progresses, increasing IL-1α, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-21, IL-23, IL-33, TGF-β decreasing IL-12A, IL-18, IFN—γ, TNFα cytokines invasive carcinoma stage being detected. over-expression COX-2, PD-1/PD-L1, CTLA-4, ICOS/ICOSLG adenomatous cancerous also observed. Conclusions: Further are needed better understanding whole picture adenoma-associated immunity its impact precancerous lesion’s potential progress.
Language: Английский
Citations
0
Asian Journal of Pharmaceutical and Clinical Research, Journal Year: 2025, Volume and Issue: unknown, P. 31 - 43
Published: April 7, 2025
The aim of this research is to assess the effect berberine and baicalein oridonin (ORI) treatment on colorectal cancer (CRC) cells. examines how these compounds bring about cellular alterations, stop cell cycle progression, trigger death. cancer-fighting agents together with ORI demonstrate strong anticancer properties against CRC tissues through metabolic instability arrest leading apoptosis. affects activation TP53/TCF4 mechanisms which creates endoplasmic reticulum stress then leads higher reactive oxygen species production alongside calcium ion imbalances. retinoid X receptor alpha mechanism performs better than in colon growth inhibition. Berberine suppresses progression its ability influence transforming factor-beta signaling pathway inhibitory action epithelial-mesenchymal transition weakening liver metastasis. altered composition gut microbes reduces tissue tumorigenesis as well total microbial abundance. shows anti-metastatic capabilities by blocking actions matrix metallopeptidase (MMP)-2 MMP-9 enzymes play important roles cells spreading during suppression occurs berberine-mediated G2/M death that results cyclin B1 cdc2 cdc25c protein downregulation. anti-inflammatory agent acts a major element developing tumorous lesions associated colitis. compound speeds up phase role regulating toll-like 4/nuclear factor-kappa B HT-29 regulatory process decrease stems from inflammation while also restricting multiplication.
Language: Английский
Citations
0
Gastroenterology report, Journal Year: 2025, Volume and Issue: 13
Published: Jan. 1, 2025
Abstract Background Colorectal cancer (CRC) is one of the most aggressive malignancies digestive tract, characterized by aberrant post-transcriptional RNA modifications, including pseudouridine (Ψ). TruB synthase family member 1 (TRUB1) a key but its role in CRC progression remains unclear. Methods Public databases and cell lines were analysed to assess TRUB1 expression CRC. Receiver-operating characteristic (ROC) curve analysis survival performed evaluate diagnostic prognostic significance TRUB1. The impact on tumor proliferation Ψ modification was examined TRUB1-knock-down HCT116 lines. Mechanistically, sequencing control cells conducted identify potential pathways, which validated using real-time polymerase chain reaction (PCR), Western blot, immunofluorescence assays. Results significantly upregulated tissues ROC showed that had strong overexpression associated with poorer overall patients. In cells, apoptosis increased growth slowed nude mice, corresponding increase apoptosis-related proteins decreased modification. indicated necrosis factor α signaling via nuclear kappa B (NFκB) pathway activated cells. Further identified Baculoviral inhibitor repeat-containing 3 (BIRC3) as downstream target gene regulated NFκB pathway. Conclusions serves biomarker for diagnosis prognosis, it can inhibit BIRC3-mediated signaling.
Language: Английский
Citations
0
Expert Opinion on Therapeutic Targets, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 23
Published: May 5, 2025
Despite decreasing trends in incidence, colorectal cancer (CRC) is still a major contributor to malignancy-related morbidities and mortalities. Groundbreaking advances immunotherapies targeted therapies benefit subset of CRC patients, with sub-optimal outcomes. Hence, there an unmet need design manufacture novel therapies, especially for advanced/metastatic disease. KRAS, the most highly mutated proto-oncogene across human malignancies, particularly pancreatic adenocarcinoma, non-small cell lung cancer, CRC, on-off switch governs several fundamental signaling cascades. KRAS mutations not only propel progression metastasis but also critically modulate responses therapies. We discuss impacts on CRC's tumor microenvironment describe strategies targeting its associated cascades mechanisms drug resistance. Drug development against has been challenging, mainly due structural properties (offering no appropriate binding site small molecules), critical functions wild-type non-cancerous cells, complex network downstream effector pathways (allowing malignant cells develop resistance). Pre-clinical early clinical data offer promises combining inhibitors
Language: Английский
Citations
0
Non-coding RNA Research, Journal Year: 2025, Volume and Issue: unknown
Published: May 1, 2025
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 371 - 371
Published: Jan. 23, 2025
Background/Objectives: The progression of colorectal cancer through clinically and histopathologically well-defined stages is driven by specific mutations that activate oncogenes or inactivate tumor-suppressor genes. In addition, pre-cancerous/cancer cells respond to cues from the tissue microenvironment support tumorigenesis progression, many which are transmitted integrin receptors for extracellular matrix. Integrin α3β1 has pro-tumorigenic/pro-metastatic roles in cancers, but it also suppressive some cancers at indicating its potential value as a therapeutic target cannot be extrapolated across types stages. this study, we investigated using cellular genetic models represent different Methods: We generated mice with colon-specific α3 knockout tamoxifen-inducible model KRAS-mutated assess effects ablation on early dysplasia. used siRNA suppress human cells, then assessed motility invasion vitro. Results: Genetic deletion colon did not alter dysplasia predisposed cancer, was accompanied an increase colocalization α6 laminin-332 (a matrix ligand both integrins), suggesting functional compensation. However, suppression caused approximately 40% 60% reduction motility/invasion cells. Conclusions: Our findings required pre-cancerous promotes cell indicate important role pro-migratory functions later when invade primary tumor, strategies should aimed distinct disease progression.
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 521 - 521
Published: Feb. 4, 2025
Background/Objectives: Colorectal cancer (CRC) arises from the epithelial lining of colon or rectum, often following a progression benign adenomatous polyps to malignant carcinoma. Screening modalities such as colonoscopy, faecal immunochemical tests (FIT), and FIT-DNA are critical for early detection prevention, but non-invasive methods lack sensitivity CRC. Chromosome conformations (CCs) potent epigenetic regulators gene expression. We have previously developed an assay, EpiSwitch®®, that employs algorithmic-based CCs analysis. Using EpiSwitch®® technology, we shown presence cancer-specific in peripheral blood mononuclear cells (PBMCs) primary tumours patients with melanoma prostate cancer. EpiSwitch®®-based commercial now available diagnose 94% accuracy (PSE test) response immune checkpoint inhibitors across 14 cancers 85% (CiRT test). Methods/Results/Conclusions: samples collected n = 171 CRC, 44 colorectal 110 ‘clear’ colonoscopy performed whole Genome DNA screening correlating CRC diagnosis. Our findings suggest two eight-marker CC signatures (EpiSwitch®® NST) allow diagnosis precancerous polyps, respectively. Independent validation cohort testing demonstrated high identifying versus late stages exceptionally 79–90% positive prediction value 60–84%. Linking top diagnostic nearby genes, built pathways maps likely underline processes contributing pathology polyp progression, including TGFβ, cMYC, Rho GTPase, ROS, TNFa/NFκB, APC.
Language: Английский
Citations
0